Evommune doses first patient in Phase 2b trial of EVO756 for migraine prevention
The company's oral MRGPRX2 antagonist enters mid-stage testing with roughly 330 patients, and top-line results are expected in 2027.
SEC filing
Latest
Thursday, July 30
Tvardi selects ulcerative colitis as first indication for TTI-109, sets KOL webinar
The company cites Phase 1 immune cell data and unveils plans for a 2027 UC trial, with an August 19 webinar featuring Dr. Randy Longman.
SEC filing
ImmunityBio wins UAE authorization for ANKTIVA in bladder cancer and lung cancer
The Emirates Drug Establishment cleared ANKTIVA for BCG-unresponsive bladder cancer and metastatic NSCLC, marking the drug's 34th country authorization.
SEC filing
Mesoblast reports $36M quarterly Ryoncil revenue, $115M for first full year
The cell therapy maker also hit its 300-patient enrollment target in a Phase 3 back pain trial and drew down $50M more from a credit facility.
SEC filing
Agios reports Q2 2026 results, sickle cell filing gets FDA priority review
Agios said its mitapivat sNDA in sickle cell disease has a PDUFA date of November 1, 2026, while it licensed cevidoplenib and dropped tebapivat from two programs.
SEC filing
Neogen posts Q4 FY26 core growth, updates on Petrifilm shift and genomics sale timeline
Food safety core growth hit its best pace since fiscal 2023 as Neogen advanced its Petrifilm manufacturing move and the pending Zoetis genomics divestiture.
SEC filing
Alterity says FDA confirmed registrational path for ATH434 in MSA
The company reported an End-of-Phase 2 agreement allowing one pivotal Phase 3 trial plus supporting evidence, with Phase 3 activities targeted to start by year-end 2026.
SEC filing
Results post for old USC gastric cancer trial; Bristol Myers Squibb opens new Zeposia PML study
Sanofi registers alirocumab cardiovascular outcomes study; RSV+HMPV vaccine trial recruiting
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial misses
Regeneron's second-quarter release recaps June 2026 FDA and EMA acceptance of cemdisiran filings for generalized myasthenia gravis and a Phase 3 fianlimab trial that missed its primary endpoint.
SEC filing
New Phase 2a trial registered for Amgen's xaluritamig after lutetium-177 therapy
NextPoint Therapeutics discloses $48.7 million private securities offering
A Form D filed with the SEC shows the Cambridge biotech has sold $33.7 million of a planned $48.7 million equity offering to 15 investors.
SEC filing
Neurocrine reports Q2 2026 results, raises INGREZZA guidance, cites 2027 pipeline readouts
The company pointed to 2027 Phase 3 data for osavampator and direclidine while reporting new CAHtalyst and VYKAT XR results and a completed Soleno acquisition.
SEC filing
Amneal raises 2026 guidance again, reprices term loan, moves ahead on Kashiv deal
The company's second raise of full-year guidance this year came alongside a $2.084 billion term loan repricing and plans for $350 million in new debt to help fund the pending Kashiv BioSciences acquisition.
SEC filing
Lite Strategy buys back 13% of shares since December, boosting Litecoin backing per share
The company repurchased about 4.9 million shares at an average price of $1.11 through treasury operations, funded without any debt.
SEC filing
Phathom to start Phase 3 as-needed VOQUEZNA trial in Q4 2026
Phathom reported record Q2 2026 revenue, updated full-year guidance, and set a fourth-quarter 2026 start for a new Phase 3 GERD trial plus EoE readout timing.
SEC filing
Myriad Genetics reports Q2 2026 revenue decline, launches efficiency initiative, cuts guidance
Myriad Genetics posted an 11% year-over-year revenue drop to $190.7 million and revised its full-year 2026 guidance while advancing several diagnostic programs.
SEC filing
Contineum reports Q2 2026 results, affirms IPF and MDD trial timelines
Contineum said its Phase 2 PROPEL-IPF trial for PIPE-791 is expanding sites while partner Johnson & Johnson finished enrolling its Phase 2 depression trial of JNJ-5120/PIPE-307.
SEC filing
FDA advisory panel votes against Deramiocel for DMD cardiomyopathy, 9 to 3
Capricor's Deramiocel fell short in a non-binding FDA advisory committee vote, though the panel's PUL 2.0 discussion was more favorable, with a PDUFA date set for August 22, 2026.
SEC filing
Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipeline
The company lowered full-year TTR sales guidance while reporting new Phase 2 starts, an FDA priority review for a partnered drug, and expanded AI collaborations.
SEC filing
FDA advisory committee backs RP1 efficacy data in advanced melanoma, 10-3
The panel found IGNYTE study results evaluable and clinically meaningful ahead of an August 2, 2026 FDA action date for Replimune's BLA resubmission.
SEC filing (2)
Bicycle Therapeutics reports Q2 2026 pipeline progress, cash into 2030
The company dosed its first pancreatic cancer patient in a nuzefatide pevedotin Phase 2 trial and reported $510.1 million in cash as of June 30, 2026.
SEC filing
Wave Life Sciences reports Q2 2026 results, advances obesity and AATD pipelines
Wave began dosing in a higher-BMI cohort of its INLIGHT obesity trial and secured an FDA meeting on accelerated approval for its AATD candidate WVE-006.
SEC filing
AstraZeneca posts Phase III baxdrostat hypertension results; registers new myeloma CAR-T trial
PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidance
Sephience sales drove product revenue growth as the company reported net income and advanced its Huntington's disease and Friedreich's ataxia programs.
SEC filing
Madrigal advances MGL-2086 into Phase 1, adds resmetirom patents, posts Q2 2026 results
Madrigal dosed the first subjects in a Phase 1 trial of its oral GLP-1 candidate MGL-2086 and gained three new resmetirom patents, while Rezdiffra sales rose 71% to $364.3 million.
SEC filing
NanoViricides closes $3.8 million offering, cuts ATM capacity to zero
The registered direct offering closed July 27, 2026, while a same-day amendment shows the company's at-the-market facility now caps eligible sales at zero.
SEC filing (3)
Annexon sets up $200 million loan facility with Oxford Finance
The biopharma company drew $50 million at closing, with more available as its two late-stage programs hit certain milestones.
SEC filing
Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programs
The company raised full-year revenue and EPS guidance and disclosed new regulatory and trial milestones for Reblozyl, mezigdomide, Camzyos and iza-bren.
SEC filing
HUTCHMED posts H1 2026 revenue of $278.3M as China sales rebound and ATTC pipeline advances
Net income fell to $15.9 million from $455.0 million a year earlier, a decline driven by a large one-time gain in 2025, while ELUNATE and SULANDA sales each grew over 40%.
SEC filing
Amneal wins FDA supplement approval for mycophenolate mofetil oral suspension REMS update
Wednesday, July 29
BNB Plus Corp ends Cypress agreements, chairman to resign
The company will pay $1,000,000 and issue preferred shares to settle terminated crypto advisory deals, and Chairman Josh Kruger will resign July 31, 2026.
SEC filing
Dyne reports Q2 2026 results as FDA accepts BLA for z-rostudirsen
Dyne's exon 51 DMD therapy gets priority review with a January 2027 PDUFA date, while the company advances DM1 and FSHD programs and reports $898.5 million in cash.
SEC filing
Spruce Biosciences' expanded access program for tralesinidase alfa in MPS IIIB listed as available
Bausch Health raises 2026 guidance after second-quarter revenue climbs 13%
The company reported $2.85 billion in second-quarter revenue and lifted its full-year outlook, citing growth at the Salix and Bausch + Lomb segments.
SEC filing
Kodiak Sciences recruiting Phase 3 ALTO trial testing tabirafusp tedromer vs. aflibercept in DME
Amarin posts Q2 2026 results as international partner sales grow, US expenses fall
Amarin said global in-market demand for VASCEPA/VAZKEPA rose 59% year over year while operating expenses excluding restructuring dropped 38%, with cash at $314.6 million.
SEC filing
Viking reports Q2 2026 results, VANQUISH trials fully enrolled, oral Phase 3 slated for 4Q26
Viking Therapeutics said its two subcutaneous VK2735 Phase 3 obesity trials are fully enrolled while it prepares to start an oral Phase 3 program and ended the quarter with $502 million in cash.
SEC filing
Kura Oncology updates severance terms for CEO and two other executives
The company revised employment agreements for Troy Wilson, Brian Powl, and Kathleen Ford, changing certain severance provisions tied to termination and change-in-control scenarios.
SEC filing
Enlivex to hold webinar on $400 million placement, RAIN treasury, and Allocetra RMAT tag
The company set a July 30 webinar to walk investors through its recent capital raise, crypto treasury plan, and new FDA designation for its knee osteoarthritis therapy.
SEC filing (2)
uniQure reaffirms Q3 2026 BLA plans for AMT-130 in Huntington's disease
The company says four-year Phase I/II data are expected in September 2026, alongside early AMT-260 epilepsy data and a $259 million raise extending its cash runway into 2030.
SEC filing
BioHarvest Sciences to present at Canaccord Genuity growth conference in August
CEO Zaki Rakib will speak at the conference in Boston and hold investor meetings, the company said in a filing dated July 29, 2026.
SEC filing
Change Agents Corporation refinances loan, adds $10M equity line
The company entered a new $825,000 business loan and a separate equity purchase agreement worth up to $10 million, both disclosed in filings dated July 2026.
SEC filing (2)
HCW Biologics prices $1.6 million private placement offering
The Nasdaq-listed company said it will use proceeds to fund clinical trials for HCW9302 and advance two pipeline candidates, with insiders including its CEO among the investors.
SEC filing
CDT Equity issues 32,110 shares to consultant for services
CDT Equity Inc. disclosed a July 24, 2026 stock issuance to a service provider, made without registering the shares under securities law.
SEC filing
BioStem Technologies files S-1 for resale of up to 3.57 million shares
The Florida-based tissue allograft maker disclosed going-concern doubt tied to CMS reimbursement cuts, BioTissue-related obligations, and an existing loan.
SEC filing
BeOne Medicines registers Phase 2 tislelizumab dosing study in Japanese ESCC patients
GlucoTrack amends note exchange terms, changes minimum price calculation date
The company's amended agreement ties share pricing to the exchange agreement's execution date rather than each individual exchange request.
SEC filing (2)